Steven Reed | Chief Executive Officer
HDT Bio Corp

WVIC/WAC Pre-Congress Workshops - Nov 28 @ 14:00

Workshop A [Room: Constellation A]

2pm: Chair opening remarks: Rebecca Kurnat M.S., Head of Product, SaponiQx

Presentations: 2.10pm – 4.00pm:

Using synthetic biology in adjuvant technology & creating a pipeline of vaccine adjuvants

Dr John Baldoni, Head of Science, SaponiQx

Next generation TLR agonists & RIG-I as adjuvants

Dr Steve Reed, CEO, HDT Bio

An oral adjuvant to augment vaccine effectiveness

Dr Upendra Marathi, President & CEO, 7Hills Pharma

Long-lasting germinal center responses to a priming immunization with continuous proliferation and somatic mutation

Dr Harry Sutton, Post-doctoral Fellow, Center for Infectious Disease and Vaccine Research, LaJolla Institute for Immunology

4.00-5:00pm Q&A and Panel Discussion with all speakers

• What are the limitations of current adjuvants?
• Importance of unique formulations & combination adjuvants
  • Kinetics, localization, dose sparing
• Ensuring a secure supply of known adjuvants
  • Rapid response and stockpiling
• Emerging concepts in adjuvant science
• What mechanisms are required to advance vaccines?
• Novel adjuvant technology – synthetic adjuvants
• Development of an adjuvant pipeline – can new adjuvants rescue previously failed vaccines?
• What factors drive clinical failure?

Rebecca Kurnat M.S., Head of Product, Saponiqx

×

Rebecca Kurnat M.S. / Workshop A [Room: Constellation A]

Rebecca Kurnat M.S., Head of Product,
Saponiqx

Executive with the ability to provide strategic leadership across all phases of drug development based upon 20 years’ experience managing large, technically complex, programs and product portfolios, with increasing influence from academia through private industry, in pursuit of Food and Drug...

CloseMore

Steven Reed, Chief Executive Officer, HDT Bio Corp

×

Steven Reed / Workshop A [Room: Constellation A]

Steven Reed, Chief Executive Officer,
HDT Bio Corp

Steve Reed is the co-founder, President, and CEO of HDT Bio, based in Seattle, USA. His academic appointments include Adjunct Professor of Medicine at Cornell University Medical College Research Professor of Pathobiology at the University of Washington. Dr. Reed received a PhD in Microbiology and...

CloseMore

Upendra Marathi, Chief Executive Officer, 7 Hills Pharma LLC

×

Upendra Marathi / Workshop A [Room: Constellation A]

Upendra Marathi, Chief Executive Officer,
7 Hills Pharma LLC

Upendra Marathi, PhD, MBA is the CEO and a co-founder of 7 Hills Pharma.  He is an inventor of their first-in-concept technology and a significant investor in the company. He has led the development of three novel pain and cardiovascular drugs, including one recently approved by the FDA. He...

CloseMore

John Baldoni, Head of Science, Saponiqx

×

John Baldoni / Workshop A [Room: Constellation A]

John Baldoni, Head of Science,
Saponiqx

Dr. John Baldoni has developed an expansive portfolio over 40+ years in the pharmaceutical industry. His previous positions include Senior Vice President of Drug Discovery, and Senior Vice President of Platform Technology and Science (PTS) at GSK Pharma R&D. His experience spans chemical entity ...

CloseMore

Harry Sutton, Post-doctoral Fellow, Center for Infectious Disease and Vaccine Research,, La Jolla Institute for Allergy and Immunology

×

Harry Sutton / Workshop A [Room: Constellation A]

Harry Sutton, Post-doctoral Fellow, Center for Infectious Disease and Vaccine Research,,
La Jolla Institute for Allergy and Immunology

Harry Sutton is Post-doctoral Scholar in the Crotty lab at the La Jolla Institute for Immunology. He completed his PhD in 2021 at the John Curtin School of Medical Research in Canberra, Australia. His primary research interests have been studying how B cells respond to vaccine targets of infectious ...

CloseMore

WVIC/WAC Day 2 - Nov 30 @ 09:00

Global Health Goals – can we get back on track?

• How has the pandemic affected the status of the epidemics of tuberculosis, malaria and neglected tropical diseases?
• Silver linings – new investments in immunization infrastructure – understanding of barriers and opportunities in promoting vaccination within communities and countries. How do we try to capitalize on some of the new pathways generated because of covid?
• How will malaria vaccines be implemented? How does this vaccine need to be promoted differently to previous vaccines? How to communicate value of vaccines in burdened communities. Integrated strategy required.
• TB vaccines how are we moving forward? Next steps for TB vaccines.

Steven Reed, Chief Executive Officer, HDT Bio Corp

×

Steven Reed / Global Health Goals – can we get back on track?

Steven Reed, Chief Executive Officer,
HDT Bio Corp

Steve Reed is the co-founder, President, and CEO of HDT Bio, based in Seattle, USA. His academic appointments include Adjunct Professor of Medicine at Cornell University Medical College Research Professor of Pathobiology at the University of Washington. Dr. Reed received a PhD in Microbiology and...

CloseMore

Yannick Vanloubbeeck, Head of Immunology, GSK

×

Yannick Vanloubbeeck / Global Health Goals – can we get back on track?

Yannick Vanloubbeeck, Head of Immunology,
GSK

Yannick Vanloubbeeck (DVM, PhD) is Head of Immunology at GSK Vaccines R&D, based in Belgium. He has joined GSK Vaccines in 2006 to lead the preclinical development of vaccine candidates against diseases of the developing world, including malaria & tuberculosis. In his current role he is...

CloseMore

Ashley Birkett, Global Head, Malaria Vaccines and Biologics, PATH

×

Ashley Birkett / Global Health Goals – can we get back on track?

Ashley Birkett, Global Head, Malaria Vaccines and Biologics,
PATH

Ashley Birkett is the Global Head of Malaria within PATH’s Center for Vaccine Innovation and Access (CVIA) and serves on the CVIA Leadership Team. CVIA brings together expertise across every stage of vaccine research, development, and introduction to make vaccines globally available to...

CloseMore

Alison Kraigsley, Program Officer, TB Vaccines, The Bill & Melinda Gates Foundation

×

Alison Kraigsley / Global Health Goals – can we get back on track?

Alison Kraigsley, Program Officer, TB Vaccines,
The Bill & Melinda Gates Foundation

Alison Kraigsley is the TB Vaccines Program Officer at the Bill and Melinda Gates Foundation and is responsible for developing and managing a portfolio of research investments to address scientific gaps and support the development of a robust TB vaccine pipeline. Alison has a broad background in...

CloseMore